Themis Medicare Ltd
Themis Medicare is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.[1]
- Market Cap ₹ 2,033 Cr.
- Current Price ₹ 220
- High / Low ₹ 266 / 109
- Stock P/E 44.9
- Book Value ₹ 39.6
- Dividend Yield 0.23 %
- ROCE 19.7 %
- ROE 17.3 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 36.9% CAGR over last 5 years
Cons
- Earnings include an other income of Rs.24.2 Cr.
- Debtor days have increased from 122 to 149 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
158 | 174 | 195 | 202 | 232 | 217 | 210 | 184 | 202 | 231 | 395 | 354 | 364 | |
171 | 157 | 171 | 184 | 194 | 184 | 184 | 181 | 166 | 181 | 299 | 287 | 311 | |
Operating Profit | -13 | 17 | 24 | 18 | 38 | 33 | 25 | 2 | 36 | 49 | 96 | 67 | 53 |
OPM % | -8% | 10% | 12% | 9% | 16% | 15% | 12% | 1% | 18% | 21% | 24% | 19% | 14% |
3 | 3 | 5 | 13 | 3 | 4 | 6 | 5 | 12 | 13 | 18 | 25 | 24 | |
Interest | 14 | 15 | 16 | 15 | 12 | 12 | 12 | 12 | 13 | 13 | 9 | 10 | 10 |
Depreciation | 8 | 9 | 9 | 11 | 12 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 12 |
Profit before tax | -31 | -4 | 4 | 5 | 17 | 18 | 11 | -13 | 27 | 41 | 95 | 73 | 55 |
Tax % | -4% | -56% | 32% | -20% | 11% | 9% | 1% | 15% | 8% | 14% | 23% | 22% | |
-32 | -6 | 3 | 6 | 16 | 16 | 11 | -11 | 25 | 36 | 73 | 57 | 45 | |
EPS in Rs | -4.03 | -0.79 | 0.32 | 0.73 | 1.91 | 1.77 | 1.23 | -1.17 | 2.70 | 3.88 | 7.92 | 6.18 | 4.92 |
Dividend Payout % | -2% | -11% | 28% | 25% | 9% | 0% | 0% | 0% | 6% | 11% | 6% | 8% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 11% |
3 Years: | 21% |
TTM: | 3% |
Compounded Profit Growth | |
---|---|
10 Years: | 27% |
5 Years: | 37% |
3 Years: | 30% |
TTM: | -23% |
Stock Price CAGR | |
---|---|
10 Years: | 44% |
5 Years: | 49% |
3 Years: | 97% |
1 Year: | 94% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 16% |
3 Years: | 21% |
Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
Reserves | 50 | 43 | 48 | 51 | 66 | 143 | 160 | 149 | 174 | 209 | 278 | 330 | 355 |
151 | 155 | 148 | 140 | 128 | 82 | 80 | 82 | 100 | 87 | 80 | 92 | 95 | |
71 | 65 | 79 | 77 | 73 | 54 | 56 | 74 | 67 | 65 | 61 | 82 | 90 | |
Total Liabilities | 280 | 272 | 284 | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 548 |
134 | 124 | 121 | 122 | 117 | 124 | 126 | 123 | 116 | 133 | 144 | 162 | 166 | |
CWIP | 7 | 11 | 12 | 4 | 6 | 9 | 2 | 2 | 8 | 2 | 3 | 3 | 3 |
Investments | 1 | 4 | 4 | 5 | 6 | 23 | 24 | 27 | 35 | 45 | 56 | 70 | 80 |
139 | 134 | 147 | 146 | 146 | 133 | 153 | 162 | 191 | 191 | 225 | 279 | 300 | |
Total Assets | 280 | 272 | 284 | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 548 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-14 | 4 | 8 | 19 | 26 | -2 | 8 | 11 | 0 | 57 | 34 | 16 | |
-12 | -5 | -7 | -6 | -7 | -4 | -0 | -4 | -5 | -16 | -16 | -24 | |
5 | 29 | 2 | -18 | -13 | 5 | -9 | -10 | 7 | -26 | -18 | 0 | |
Net Cash Flow | -21 | 29 | 4 | -5 | 5 | -0 | -1 | -3 | 2 | 16 | 1 | -8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 111 | 68 | 74 | 82 | 75 | 81 | 120 | 145 | 186 | 123 | 93 | 149 |
Inventory Days | 174 | 246 | 280 | 246 | 243 | 250 | 253 | 287 | 315 | 272 | 150 | 213 |
Days Payable | 217 | 232 | 240 | 237 | 145 | 163 | 156 | 187 | 171 | 143 | 79 | 123 |
Cash Conversion Cycle | 68 | 82 | 114 | 91 | 172 | 168 | 216 | 244 | 330 | 251 | 164 | 239 |
Working Capital Days | 110 | 87 | 81 | 78 | 64 | 74 | 131 | 132 | 176 | 152 | 124 | 176 |
ROCE % | -8% | 5% | 10% | 9% | 15% | 13% | 10% | -1% | 15% | 18% | 30% | 20% |
Documents
Announcements
- Closure of Trading Window 1d
- Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Mar
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 8 Mar
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 29 Feb
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
23 Feb - Refer to the attached intimation for the captioned subject.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Feb 2023Transcript PPT REC
-
Nov 2022Transcript PPT
Product Portfolio
The company manufactures and markets bulk APIs of synthetic and biotech origin, bulk intermediates, and formulations. In the formulations segment, the company manufactures anti-TB, anti-malarial, anti-cholesterol, and pain management drugs. [1]
The company manufactures 190+ different drugs for ~20 different therapeutic areas. [2]